X

Aggrego On Site

Top Stories
More NSCLC Downstaging With Neoadjuvant Chemotherapy Plus ICI

Neoadjuvant chemotherapy plus nivolumab resulted in a higher frequency of disease downstaging and lower frequency of upstaging compared with other therapies among patients with...

Cancer Therapy Advisor
11/12/2020
OncoMyx’s Oncolytic Virus Platform Shows Preclinical Efficacy, Boosting Immunotherapy Potential

Only about one in seven cancer patients today benefit from immunotherapy. OncoMyx aims to increase this number, using a new multi-armed, systemically administered and targeted onco

11/17/2020
``

SITC Conference Coverage 2020

SITC 2020 SCIENTIFIC HIGHLIGHTS – NOV. 13, 2020

The SITC is pleased to present scientific highlights from the Nov. 13, 2020, sessions of the 35th Anniversary Annual Meeting.

11/13/2020
OncoMyx’s Oncolytic Virus Platform Shows Preclinical Efficacy, Boosting Immunotherapy Potential

Only about one in seven cancer patients today benefit from immunotherapy. OncoMyx aims to increase this number, using a new multi-armed, systemically administered and targeted onco

11/17/2020
Pseudoprogression With Immunotherapy in Cervical Cancer

Pseudoprogression with ICIs was observed in a cohort of patients with recurrent cervical cancer, including early, delayed, and serial events, according to the results of a study presented at the...

Cancer Therapy Advisor
11/12/2020
SITC 2020 SCIENTIFIC HIGHLIGHTS – NOV. 14, 2020

The SITC is pleased to present scientific highlights from the Nov. 14, 2020, sessions of the 35th Anniversary Annual Meeting.

11/14/2020
Combination Drug Strategies Gain Ground in Global Immuno-Oncology Pipeline of PD-1 and PD-L1 Clinical Trials, New Report from Cancer Research Institute Reveals

The CRI announced today the publication in Nature Reviews Drug Discovery of its newest analysis of the global landscape of PD-1/PD-L1 inhibitor drug development for cancer treatment.

11/11/2020
More NSCLC Downstaging With Neoadjuvant Chemotherapy Plus ICI

Neoadjuvant chemotherapy plus nivolumab resulted in a higher frequency of disease downstaging and lower frequency of upstaging compared with other therapies among patients with...

Cancer Therapy Advisor
11/12/2020

ASH 2020

Alfred Garfall: Evaluating Teclistamab in Relapsed and/or Refractory Multiple Myeloma

Dr. Alfred Garfall discusses evaluating teclistamab in relapsed and/or refractory multiple myeloma.

12/05/2020
ViPOR Yields Complete Response in Patients with R/R B-Cell NHL

In a phase 1b/2 study of patients with relapsed/refractory B-cell non-Hodgkin's lymphoma, the ViPOR regimen led to complete responses, with no unexpected toxicities.

Oncology Learning Network
12/17/2020
Jacqueline Garcia: Evaluating Venetoclax Plus Azacitidine in Patients with High-Risk MDS

Dr. Jacqueline Garcia discusses evaluating venetoclax plus azacitidine in patients with high-risk MDS.

12/07/2020
What plasma short-chain fatty acids are predictors of response to GvHD therapy?

Holtan describes the results of a clinical trial evaluating how acute GvHD treatment response relates to plasma levels of short-chain fatty acids.

12/14/2020
ASH 2020: Highlights for GvHD

GvHD Hub Chair Mohamad Mohty, Hôpital Saint-Antoine and Sorbonne University, Paris, FR, provides the highlights for GvHD from the 62nd ASH Annual Meeting and Exposition.

12/14/2020

ASH 2020 Highlights – DLBCL

CD22-Directed CAR T-Cell Therapy Induces Complete Remissions in CD19-Directed CAR-Refractory Large B-Cell Lymphoma

This study reports on the first three consecutive patients with autologous CAR19-refractory LBCL treated with a single infusion of autologous 1×106 CAR+ T-cells/kg targeting...

Blood
12/18/2020
Durable Responses Seen With Odronextamab in Refractory B-Cell NHLs

Odronextamab, demonstrated promising antitumor activity and an acceptable safety profile — including with cytokine release syndrome (CRS)–mitigating strategies — among patients with B-cell NHLs.

Cancer Therapy Advisor
12/07/2020
CAR T cells or allogeneic transplantation as standard of care for advanced large B-cell lymphoma: an intent-to-treat comparison

The prognosis for patients with LBCL, such as DLBCL, high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements/double-hit lymphoma, and primary mediastinal B-cell....

Blood Advances
12/11/2020
Phase II ZUMA-12 Study Investigates First-Line Axicabtagene Ciloleucel for High-Risk Large B-Cell Lymphoma

The phase II ZUMA-12 trial found axicabtagene ciloleucel, an autologous anti-CD19 CAR T-cell therapy, is a safe and effective first-line therapy for patients with high-risk large B-cell lymphoma.

The ASCO Post
12/11/2020
Long-Lasting Remission With Dual Targeting CAR-T Therapy for R/R DLBCL

Patients with relapsed/refractory DLBCL given AUTO3 in combination with pembrolizumab experienced durable complete remissions, according to data presented by Aravind Ramakrishnan, MD.

Oncology Learning Network
12/18/2020
ctDNA May Indicate Increased Risk of Relapse After Stem Cell Transplant in Patients With DLBCL

Many patients with diffuse large B-cell lymphoma may be cured by autologous stem cell transplant, but as many as half eventually relapse.

The ASCO Post
12/14/2020

ASH 2020 Highlights - GvHD

A pragmatic multi-institutional approach to understanding transplant-associated thrombotic microangiopathy after stem cell transplant

Transplant-associated thrombotic microangiopathy is a severe complication of hematopoietic stem cell transplantation.

Blood Advances
12/23/2020

Clinical Trials Offer Opportunities to Change Practice to Improve Prevention and Treatment of Blood Disorders

12/04/2020
Podcast: ASH 2020 Top Science

Among the research at this year's ASH virtual meeting, investigators presented noteworthy findings on an innovative gene therapy for sickle cell disease, CAR T-cell therapy...

MedPage Today
12/14/2020
In Utero Hematopoietic Cell Transplantation Safe in Fetuses with Alpha Thalassemia Major

In utero hematopoietic cell transplantation with maternal cells was safe in two fetuses with alpha thalassemia major, according to interim results of a phase I clinical trial.

12/15/2020
ALLO-715 Found to Be Effective Against Multiple Myeloma

ALL0-715 is a genetically modified anti-BCMA AlloCAR T cell product in which the TCR alpha constant gene is disrupted in order to reduce the risk of graft-versus-host disease.

12/16/2020

TCT Meetings Symposium

Strategies for Dodging the Obstacles in CAR T Cell Therapy

CAR T cell therapy has experienced its ups and downs in terms of toxicities and efficacy shortcomings.

Frontiers in Oncology
04/01/2021
Efficacy and Safety of Chimeric Antigen Receptor T-Cell Therapy for Relapsed/Refractory Immunoglobulin D Multiple Myeloma

This study is designed to investigate efficacy and safety of chimeric antigen receptor T-cell therapy for relapsed/refractory IgD MM (R/R IgD MM).

Transplantation and Cellular Therapy
03/15/2021
The BCMA-Targeted Fourth-Generation CAR-T Cells Secreting IL-7 and CCL19 for Therapy of Refractory/Recurrent Multiple Myeloma

Study investigators construct the BCMA-targeted fourth-generation CAR-T cells expressing IL-7 and CCL19, and demonstrate that BCMA-7 × 19 CAR-T cells exhibit...

Frontiers in Immunology
03/05/2021
CAR T Cell Therapy Shows Benefits in Patients With R/R Indolent Non-Hodgkin Lymphoma

Per results presented at the 2021 TCT Meetings, the autologous anti-CD19 CAR T-cell therapy axicabtagene ciloleucel (axi-cel) yields considerable and durable clinical benefits.

03/09/2021
Cost-Effectiveness Analysis of Tisagenlecleucel for the Treatment of Pediatric and Young Adult Patients with Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia in Japan

The objective of this study is to assess the cost-effectiveness of a tisagenlecleucel treatment strategy compared to a  blinatumomab treatment strategy and a clofarabine combination...

Transplantation and Cellular Therapy
03/15/2021
Spotlight

source list reference

#7d60d9
#2694a4
#32a887
#85eb24
#352625
#4d4537
#d2093c
#8e3f1c
#76b6c3
#bfcfc8
#c61417
#67e25b
#efef71
#03cffc
#42fc9a
#cc529a
#c59445
#c8cc0c
#bf6be3
#e8085a
#97d1a0
#74e391
#eb6342
#b61f77
#a153ac
#e7f6e3
#6fc969
#9a8c2c
#a9c507
#2b9ab3
#e61923
#990677
#4a7bab
#89f67c
#49a21d
#2c990a
#d7da81
#575662
#a60538
#49cde9
#c20fce
#d95d39